Bhanu Patibandla, MD
Pulmonary Disease · Vancouver, WANPI 1558625186
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (36.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 87.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $2,671 and has fallen 99.7% since, to $7 in 2024.
Across 45 payments — averaging $93.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Genentech USA, Inc.$82
- United Therapeutics Corporation$81
- Actelion Pharmaceuticals US, Inc.$47
- Mylan Specialty L.p.$33
- AstraZeneca$33
- plus $253 from 13 others
Across 2 payments — averaging $7906.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Galvanize Therapeutics, Inc$16K
What the payments were for
- Speaking & faculty fees$95023%
- Travel & lodging$1,51936%
- Food & beverage$1,28531%
- Education$45011%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 18 | $3,676 |
| Genentech USA, Inc. | 4 | $82 |
| United Therapeutics Corporation | 1 | $81 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Mylan Specialty L.p. | 2 | $33 |
| AstraZeneca | 2 | $33 |
| GSK | 2 | $32 |
| Boehringer Ingelheim | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 3 | $22 |
| Philips North America LLC | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Covidien LP | 1 | $19 |
| Shire North American Group Inc | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $16 |
| Pfizer | 1 | $16 |
| Pulmonx Corporation | 1 | $16 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,972
- DA VINCI SP$500
How this compares
$4,204 in reported general payments places this provider in the 80th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $152,527 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $65,727 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $29,142 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $6,757 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,872 |
| DuleraMometasone/Formoterol | 14 | $4,807 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,520 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 87 | $3,177 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $23 | $181,66940 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $70,59995 claims |
| AstraZenecaSymbicort | $33 | $3,52012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Vancouver
- Nicholas WyshamVancouver$117K
- Todd GienappVancouver$6K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
- Benjamin SyBremerton$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.